8-K
filed May 16, 2024, 7:59 PM ET
ticker BJDX
CIK 0001704287
other material
confidence high
sentiment neutral
materiality 0.75
Bluejay Diagnostics increases authorized shares from 7.5M to 50M; shareholders approve reverse stock split up to 1:10
Bluejay Diagnostics, Inc.
- Authorized shares of common stock increased from 7,500,000 to 50,000,000 via amendment filed May 14, 2024.
- Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-10; board to decide final ratio and timing.
- Directors Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani, and Douglas Wurth re-elected.
- Ratification of Wolf & Company, P.C. as independent auditor for FY2024 approved.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Bluejay Diagnostics, Inc.: Increased authorized common shares from 7,500,000 to 50,000,000 via amendment to certificate of incorporation (effective 2024-05-14).
- Change
- charter amendment
- Effective
- 2024-05-14
Exact text from the filing
On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm at the 2024-05-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-14
Exact text from the filing
Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2024-05-14 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-05-14
Exact text from the filing
Proposal 2. Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-14 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2024-05-14
Exact text from the filing
Proposal 3. Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to effect a reverse stock split of all of the Company’s outstanding shares of common stock by one of several fixed ratios between 1-for-2 and 1-for-10 (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined in the future by the Company’s board of directors, in its sole discretion and without further action by the Company’s stockholders.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bluejay Diagnostics, Inc. shareholders approved Election of directors at the 2024-05-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-14
Exact text from the filing
Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani and Douglas Wurth to serve as directors until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.